Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow

doi:10.1016/0002-9149(89)90388-3

The American Journal of Cardiology

Volume 63, Issue 2, 3 January 1989, Pages A23-A26

https://doi.org/10.1016/0002-9149(89)90388-3 Get rights and content

Abstract

The phosphodiesterase inhibitors (amrinone, milrinone and enoximone) can cause major improvement in the performance of the failing heart without increasing myocardial oxygen consumption. This appears to be the result of a reduction in left ventricular systolic wall stress due to peripheral arteriolar vasodilatation, which offsets the increase in myocardial oxygen consumption that would otherwise result from an enhanced inotropic state. In comparison, catecholamine agents such as dobutamine, given at doses that achieve the same level of inotropic enhancement or improved left ventricular performance, produce less associated arteriolar vasodilatation and a significant (approximately 30%) increase in myocardial oxygen consumption. This difference between the phosphodiesterase inhibitors and the conventional catecholamine agents may be of clinical importance in patients with limited coronary flow reserve due to severe congestive heart failure.

References (30)

E Braunwald
Control of myocardial oxygen consumption. Physiologic and clinical considerations
Am J Cardiol
(1971)
BE Strauer
Myocardial oxygen consumption in chronic heart disease. Role of wall stress, hypertrophy and coronary reserve
Am J Cardiol
(1979)
FJ Klocke
Coronary blood flow in man
Prog Cardiovasc Dis
(1976)
DV Unverferth et al.
The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy
Am Heart J
(1983)
JH Jentzer et al.
Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs
Am J Cardiol
(1981)
E Kabela et al.
The effects of milrinone (Win47203) on the coronary blood flow and oxygen consumption of the dog heart-lung preparation
Am Heart J
(1986)
JL Anderson et al.
Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure. A multicenter study
JACC
(1987)
R Grose et al.
Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure
JACC
(1986)
DK Amin et al.
Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure
Am Heart J
(1984)
JL Martin et al.
Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure
JACC
(1984)

CE Viquerat et al.

Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure

JACC

(1985)

M Petein et al.

Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure

JACC

(1984)

R Bendersky et al.

Dobutamine in chronic ischemic heart failure. Alterations in left ventricular function and coronary hemodynamics

Am J Cardiol

(1981)

DS Baim et al.

Simultaneous measurement of coronary venous blood flow and oxygen saturation during transient alterations in myocardial oxygen supply and demand

Am J Cardiol

(1982)

KT Weber et al.

The metabolic demand and oxygen supply of the heart. Physiologic and clinical considerations

Am J Cardiol

(1979)

Cited by (47)

Drugs for Cardiovascular Support in Anesthetized Horses
2013, Veterinary Clinics of North America - Equine Practice
Citation Excerpt :
Vasodilation reduces ventricular wall stress and counteracts the increased oxygen requirement normally needed to support enhanced contractility112 Lesser chronotropic effects than dobutamine111 More pronounced lusitropic effect than β-sympathomimetics113
Pharmacology of the Cardiovascular System
2011, Pediatric Critical Care: Expert Consult Premium Edition
Pharmacology of the Cardiovascular System
2011, Pediatric Critical Care
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: Results of the oral enoximone in intravenous inotrope-dependent subjects trial
2007, American Heart Journal
We determined whether low-dose oral enoximone could wean patients with ultra-advanced heart failure (UA-HF) from intravenous (IV) inotropic support. Chronic parenteral inotropic therapy in UA-HF is costly and requires an indwelling catheter. An effective and safe oral inotrope would have value.
In this placebo-controlled study, 201 subjects with UA-HF requiring IV inotropic therapy were randomized to enoximone or placebo. Subjects receiving intermittent IV inotropes were administered study medication of 25 or 50 mg 3 times a day (tid). Subjects receiving continuous IV inotropes were administered 50 or 75 mg tid for 1 week, which was reduced to 25 or 50 mg tid. The ability of subjects to remain alive and free of inotropic therapy was assessed for up to 182 days.
Thirty days after weaning, 51 (51%) subjects on placebo and 62 (61.4%) subjects in the enoximone group were alive and free of IV inotropic therapy (unadjusted primary end point P = 0.14, adjusted for etiology P = .17). At 60 days, the wean rate was 30% in the placebo group and 46.5% in the enoximone group (unadjusted P = .016) Kaplan-Meier curves demonstrated a trend toward a decrease in the time to death or reinitiation of IV inotropic therapy over the 182-day study period (hazard ratio 0.76 [95% CI 0.55-1.04]) and a reduction at 60 days (0.62 [95% CI 0.43-0.89], P = .009) and 90 days (0.69 [95% CI 0.49-0.97], P = .031) after weaning in the enoximone group.
Although there was no benefit over placebo in weaning patients from IV inotropes from 0 to 30 days, the EMOTE data suggest that low-dose oral enoximone can be used to wean a modest percentage of subjects from IV inotropic support for up to 90 days after initiation of therapy.
Pharmacology of the Cardiovascular System
2006, Pediatric Critical Care
Rationale and design of the enoximone clinical trials program
2005, Journal of Cardiac Failure
Citation Excerpt :
Enoximone has been shown to improve skeletal muscle blood flow selectively,50 which may contribute to its demonstrated beneficial effects on exercise tolerance. Enoximone has no direct effect on renal function and in failing hearts decreases or has no adverse effect on myocardial oxygen consumption.51–53 Enoximone is approximately 85% plasma protein–bound and clinically significant drug interactions are unlikely to occur as a result of displacement from protein binding.
Chronic heart failure is a disease syndrome characterized in its advanced stages by a poor quality of life, frequent hospitalizations, and a high risk of mortality. In advanced and ultra-advanced chronic heart failure, many treatment options, such as cardiac transplantation and mechanical devices, are severely limited by availability and cost. Short-term Phase II clinical trials suggest that low-dose oral inotropic therapy with enoximone may improve hemodynamics and exercise capacity, without adversely affecting mortality, in selected subjects with advanced chronic heart failure. Based on these data, the ability of enoximone to deliver safe and efficacious palliative treatment of advanced/ultra-advanced chronic heart failure is being evaluated in Phase III clinical trials.
The Enoximone Clinical Trials Program is a series of 4 clinical trials designed to evaluate the safety and efficacy of oral enoximone in advanced chronic heart failure. ESSENTIAL I and II (The Studies of Oral Enoximone Therapy in Advanced Heart Failure) will investigate the effects of oral enoximone on all-cause mortality and cardiovascular hospitalization, submaximal exercise capacity, and quality of life in subjects with New York Heart Association Class III/IV chronic heart failure. EMOTE (Oral Enoximone in Intravenous Inotrope-Dependent Subjects) will evaluate the potential of oral enoximone to wean subjects with ultra-advanced chronic heart failure from chronic intravenous inotropic therapy to which they have been shown to be dependent. EMPOWER (Enoximone Plus Extended-Release Metoprolol Succinate in Subjects with Advanced Chronic Heart Failure) will explore the potential of enoximone to increase the tolerability of continuous release metoprolol in subjects shown previously to be hemodynamically intolerant to β-blocker treatment.
These studies are Phase III, multicenter, randomized, double-blinded, placebo-controlled trials designed to test the general hypothesis that chronic oral administration of low doses of enoximone can produce beneficial effects in subjects with advanced or ultra-advanced chronic heart failure.

View all citing articles on Scopus

View full text

Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow

Abstract

Am J Cardiol

Am J Cardiol

Prog Cardiovasc Dis

Am Heart J

Am J Cardiol

Am Heart J

JACC

JACC

Am Heart J

JACC

JACC

JACC

Am J Cardiol

Am J Cardiol

Am J Cardiol